These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 30389411

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Peanut oral immunotherapy increases IgG4 to Ara h 1, 2, and 6 but does not affect IgG4 to other allergens.
    Uotila R, Kukkonen AK, Greco D, Pelkonen AS, Mäkelä MJ.
    Pediatr Allergy Immunol; 2019 Mar; 30(2):248-252. PubMed ID: 30561805
    [No Abstract] [Full Text] [Related]

  • 3. Linear epitope mapping of peanut allergens demonstrates individualized and persistent antibody-binding patterns.
    Hansen CS, Dufva M, Bøgh KL, Sullivan E, Patel J, Eiwegger T, Szépfalusi Z, Nielsen M, Christiansen A.
    J Allergy Clin Immunol; 2016 Dec; 138(6):1728-1730. PubMed ID: 27523433
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Peanut-allergic patient experiences after epicutaneous immunotherapy: peanut consumption and impact on QoL.
    Lewis MO, Brown-Whitehorn TF, Cianferoni A, Rooney C, Spergel JM.
    Ann Allergy Asthma Immunol; 2019 Jul; 123(1):101-103. PubMed ID: 30978404
    [No Abstract] [Full Text] [Related]

  • 6. Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens.
    Vickery BP, Lin J, Kulis M, Fu Z, Steele PH, Jones SM, Scurlock AM, Gimenez G, Bardina L, Sampson HA, Burks AW.
    J Allergy Clin Immunol; 2013 Jan; 131(1):128-34.e1-3. PubMed ID: 23199605
    [Abstract] [Full Text] [Related]

  • 7. Monitoring Ara h 1, 2 and 3-sIgE and sIgG4 antibodies in peanut allergic children receiving oral rush immunotherapy.
    Nozawa A, Okamoto Y, Movérare R, Borres MP, Kurihara K.
    Pediatr Allergy Immunol; 2014 Jun; 25(4):323-8. PubMed ID: 24953293
    [Abstract] [Full Text] [Related]

  • 8. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective.
    Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, Keet CA, Kulis M, Orgel KG, Guo R, Steele PH, Virkud YV, Ye P, Wright BL, Wood RA, Burks AW.
    J Allergy Clin Immunol; 2017 Jan; 139(1):173-181.e8. PubMed ID: 27522159
    [Abstract] [Full Text] [Related]

  • 9. Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research.
    Scurlock AM, Burks AW, Sicherer SH, Leung DYM, Kim EH, Henning AK, Dawson P, Lindblad RW, Berin MC, Cho CB, Davidson WF, Plaut M, Sampson HA, Wood RA, Jones SM, Consortium for Food Allergy Research (CoFAR).
    J Allergy Clin Immunol; 2021 Mar; 147(3):992-1003.e5. PubMed ID: 33290772
    [Abstract] [Full Text] [Related]

  • 10. Developing therapies for peanut allergy.
    Bublin M, Breiteneder H.
    Int Arch Allergy Immunol; 2014 Mar; 165(3):179-94. PubMed ID: 25531161
    [Abstract] [Full Text] [Related]

  • 11. Extended boiling of peanut progressively reduces IgE allergenicity while retaining T cell reactivity.
    Tao B, Bernardo K, Eldi P, Chegeni N, Wiese M, Colella A, Kral A, Hayball J, Smith W, Forsyth K, Chataway T.
    Clin Exp Allergy; 2016 Jul; 46(7):1004-14. PubMed ID: 27079163
    [Abstract] [Full Text] [Related]

  • 12. Peanut allergens.
    Palladino C, Breiteneder H.
    Mol Immunol; 2018 Aug; 100():58-70. PubMed ID: 29680589
    [Abstract] [Full Text] [Related]

  • 13. Low dose immunotherapy in very young children to treat peanut allergy.
    Vickery BP.
    Expert Rev Clin Immunol; 2016 Dec; 12(12):1251-1253. PubMed ID: 27599211
    [No Abstract] [Full Text] [Related]

  • 14. Single B-cell deconvolution of peanut-specific antibody responses in allergic patients.
    Hoh RA, Joshi SA, Liu Y, Wang C, Roskin KM, Lee JY, Pham T, Looney TJ, Jackson KJL, Dixit VP, King J, Lyu SC, Jenks J, Hamilton RG, Nadeau KC, Boyd SD.
    J Allergy Clin Immunol; 2016 Jan; 137(1):157-167. PubMed ID: 26152318
    [Abstract] [Full Text] [Related]

  • 15. Evolution of epitope-specific IgE and IgG4 antibodies in children enrolled in the LEAP trial.
    Suarez-Farinas M, Suprun M, Bahnson HT, Raghunathan R, Getts R, duToit G, Lack G, Sampson HA.
    J Allergy Clin Immunol; 2021 Sep; 148(3):835-842. PubMed ID: 33592205
    [Abstract] [Full Text] [Related]

  • 16. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study).
    Fauquert JL, Michaud E, Pereira B, Bernard L, Gourdon-Dubois N, Rouzaire PO, Rochette E, Merlin E, Evrard B, PITA Group.
    Clin Exp Allergy; 2018 Jul; 48(7):862-874. PubMed ID: 29665158
    [Abstract] [Full Text] [Related]

  • 17. Peanut allergen powder (Palforzia).
    Med Lett Drugs Ther; 2020 Mar 09; 62(1593):33-34. PubMed ID: 32555119
    [No Abstract] [Full Text] [Related]

  • 18. Current opinion and review on peanut oral immunotherapy.
    Deol S, Bird JA.
    Hum Vaccin Immunother; 2014 Mar 09; 10(10):3017-21. PubMed ID: 25483680
    [Abstract] [Full Text] [Related]

  • 19. Cross-reactivity of peanut allergens.
    Bublin M, Breiteneder H.
    Curr Allergy Asthma Rep; 2014 Apr 09; 14(4):426. PubMed ID: 24554241
    [Abstract] [Full Text] [Related]

  • 20. Immunotherapy using algal-produced Ara h 1 core domain suppresses peanut allergy in mice.
    Gregory JA, Shepley-McTaggart A, Umpierrez M, Hurlburt BK, Maleki SJ, Sampson HA, Mayfield SP, Berin MC.
    Plant Biotechnol J; 2016 Jul 09; 14(7):1541-50. PubMed ID: 26801740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.